The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Early tumor shrinkage (ETS) as clinical factor to select maintenance with cetuximab (cet) monotherapy in patients (pts) with RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC): A secondary endpoint analysis of the ERMES study.
 
Armando Orlandi
Honoraria - Amgen; Daiichi Sankyo Pharmaceutical; Lilly O.; Novartis; Pfizer
Consulting or Advisory Role - Daiichi Sankyo Pharmaceutical; Novartis; Pfizer
Research Funding - Merck KGaA
Expert Testimony - Daiichi Sankyo Pharmaceutical; Gilead Sciences; Novartis; Pfizer
Travel, Accommodations, Expenses - Gilead Sciences; Lilly O.; Novartis; Pfizer
 
Carmine Pinto
No Relationships to Disclose
 
Maria Alessandra Calegari
Honoraria - Merck; Pierre Fabre; SERVIER
Consulting or Advisory Role - Merck; Pierre Fabre; SERVIER
 
Nicola Normanno
No Relationships to Disclose
 
Evaristo Maiello
No Relationships to Disclose
 
Lorenzo Antonuzzo
No Relationships to Disclose
 
Roberto Bordonaro
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb; Janssen-Cilag; Novartis; Pfizer; Roche; Sanofi
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Janssen-Cilag; Novartis; Pfizer; Roche; Sanofi
Speakers' Bureau - Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Janssen-Cilag; Novartis; Pfizer; Roche; Sanofi
 
M. Giulia Zampino
No Relationships to Disclose
 
Francesca Bergamo
Consulting or Advisory Role - Advanced Accelerator Applications/Novartis; SERVIER
Speakers' Bureau - Bayer; Eisai; Lilly; MSD Oncology
 
Giuseppe Tonini
Consulting or Advisory Role - Italfarmaco; Molteni Farmaceutici; Novartis; Pierre Fabre; Roche
Research Funding - Novartis (Inst); PharmaMar (Inst)
 
Stefano Tamberi
No Relationships to Disclose
 
Antonio Avallone
No Relationships to Disclose
 
Tiziana Pia Latiano
No Relationships to Disclose
 
Gerardo Rosati
No Relationships to Disclose
 
Antonio Pazzola
No Relationships to Disclose
 
Alberto Ballestrero
No Relationships to Disclose
 
Alberto Zaniboni
No Relationships to Disclose
 
Vincenzo Formica
Honoraria - Amgen; Bayer; SERVIER
 
Carlo Barone
No Relationships to Disclose